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Abstract
Members of Shc (src homology and collagen homology) family, p46shc, p52shc, p66shc have known to be related to 
cell proliferation and carcinogenesis. Whereas p46shc and p52shc drive the reaction forward, the role of p66shc in 
cancers remains to be understood clearly. Hence, their expression in cancers needs to be evaluated carefully so that 
Shc analysis may provide prognostic information in the development of carcinogenesis. In the present study, the 
expression of p66shc and its associate targets namely Eps8 (epidermal pathway substrate 8), Rac1 (ras-related C3 
botulinum toxin substrate1) and Grb2 (growth factor receptor bound protein 2) were examined in fresh tissue 
specimens from patients with esophageal squamous cell carcinoma and esophageal adenocarcinoma using western 
blot analysis. A thorough analysis of both esophageal squamous cell carcinoma and adenocarcinoma showed p66shc 
expression to be significantly higher in both types of carcinomas as compared to the controls. The controls of 
adenocarcinoma show a higher basal expression level of p66shc as compared to the controls of squamous cell 
carcinoma. The expression level of downstream targets of p66shc i.e., eps8 and rac1 was also found to be consistently 
higher in human esophageal carcinomas, and hence correlated positively with p66shc expression. However the 
expression of grb2 was found to be equal in both esophageal squamous cell carcinoma and adenocarcinoma. The 
above results suggest that the pathway operated by p66shc in cancers does not involve the participation of Ras and 
Grb2 as downstream targets instead it operates the pathway involving Eps8 and Rac1 proteins. From the results it is 
also suggestive that p66shc may have a role in the regulation of esophageal carcinomas and represents a possible 
mechanism of signaling for the development of squamous cell carcinoma and adenocarcinoma of esophagus.
Findings
Shc (src homology and collagen homology domain) con-
taining proteins were cloned using an SH2-coding
sequence probe and the shc family includes three mem-
bers with molecular masses 46 kDa (p46Shc), 52 kDa
(p52Shc) and 66 kDa (p66Shc). All isoforms are generated
either RNA splicing or alternative translational initiation
[1]. P66shc has the same modular structure of p46shc/
p52shc (SH2-CH1-PTB), however it contains a unique
amino-terminal CH2 region, responsible for its distinc-
tive role in signal transduction [2]. Whereas p46Shc and
p52Shc are the two cytoplasmic adaptor proteins impli-
cated in the propagation of intracellular signals from acti-
vated tyrosine kinases to Ras, p66shc functions in the
intracellular pathways involving ROS (reactive oxygen
species) generation and apoptosis [1-3].
Unlike p46shc and p52shc, ectopic expression of
p66shc is unable to transform mouse NIH-3T3 fibro-
blasts in vitro [2]. Over expression of p66shc protein in
cell lines such as Hela, CHO and COS-1 cells does not
increase EGF-induced ERK/MAPK activation [2,4]. One
possible explanation is that increased expression of
p66shc results in elevated level of the basal activity of
ERK/MAPK in the absence of stimulus, which thus
diminishes additional activation by growth factors [2,3,5].
P66shc is phosphorylated at ser36 in its CH2 domain
under various stress signals such as H2O2, UV radiation
and exposure to chemicals, such as Taxol, and thus could
serve as an apoptotic sensitizer to stress signals [6,7].
P66shc has also been identified as a mediator of Rac-1
induced oxidative stress. Rac1 is a member of small
GTPases that play an important role in regulation of
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intracellular ROS. Expression of constitutively active Rac-
1 increased phosphorylation, reduced ubiquitination and
increased stability of p66shc protein [8]. Conversely,
p66shc activates Rac-1 through the mediation of
exchange factor Sos1 [9]. Eps8 together with E3b1
(another adaptor protein) in a complex are also involved
in the regulation of this activity of Rac1 [10]. It has been
r evea led t ha t Sos1 ca n e it he r e xists  bound t o G rb 2 or
Eps8/E3b1. While as Sos-Grb2 complex leads to Ras acti-
vation [11], the complex of Sos1/Eps8/E3b1 leads to Rac1
activation [10]. P66shc acts as a switch to dissociate Sos1
from Grb2/Sos1 pool to Eps8/E3b1 pool. This complex
formation increases the generation of oxidants through
the activation of Rac1 protein [9]. Indeed, during severe
oxidative stress, increased binding of p66shc to the acti-
vated EGFR and Grb2 occurs. This binding dissociates
the Sos1 adaptor protein from the EGFR recruited signal-
ing complex, leading to termination of Ras/MEK/ERK
activation [12] (figure representing signal transduction
pathway of p66shc protein shown in additional file
1).The data from the above study further validates its
position in signal transduction pathways stimulated by
oxidative stress. In spite of this, the role of p66shc in
human carcinogenesis remains to be understood evi-
dently.
Several lines of evidences indicate that aberrant expres-
sion of p66shc could be implied in various stages of car-
cinogenesis [13-19]. Furthermore, most of the studies
have focused on steroid-regulated cancers without much
emphasis on most prevalent cancers existing worldwide.
In the present report, we focus on the expression pattern
of p66shc and its downstream targets i.e., Eps8 and rac1
proteins in human esophageal carcinomas (one of the
most common cancer worldwide). Cancer cells constitu-
tively generate large amounts of ROS suggesting that a
certain level of oxidative stress is required for prolifera-
tion. Since there is a feedback mechanism between
p66shc and ROS generation, and ROS being actively
i n v o l v e d  i n  c a r c i n o g e n e s i s  w e  s o u g h t  t o  l o o k  f o r  i t s
expression in cancers as a prelude to its implication for
role/target for prevention of tumor progression. Because
p66shc regulates Eps8 and Rac1 function by increasing
ROS generation, we sought to study their expression pat-
tern along with p66shc.
We carried out western blot analysis (detailed materials
and methods provided in additional file 2) of p66shc in
esophageal squamous cell carcinoma (ESCC) and esoph-
ageal adenocarcinoma (EAC) from independent patients
(Table  1). Our results indicate a consistent increase in
p66shc protein levels in both carcinomas when compared
to their adjacent normal controls (Figure 1). The controls
of ESCC showed a lower basal level of p66shc expression
(Figure 1A) as compared to the higher levels found in the
controls of EAC (Figure 1B). We also carried out expres-
sion analysis on well, moderately and poorly differenti-
ated tumor samples. Results indicate (Figure 1A, C) that
the increase in p66shc expression as compared to the
normal was independent of the different grades of can-
cers studied. We also used antibody, which recognizes all
the three isoforms of ShcA family of proteins. Consistent
with the increase in the expression of p52 and p46, we
again observed a significant increase in p66shc protein
(Figure 1C). Densitometric analysis indicated 4-8 fold
increase in the level of expression of p66shc in ESCC as
against 2-3 fold increase found in EAC when compared to
adjacent normal (Figure 1D). The results obtained were
independent of age or sex.
Figure 1 Expression of p66shc protein in esophageal cancers. A 
Representative immunoblot showing the up-regulation of p66shc 
protein in poorly differentiated (PD), Moderately differentiated (MD) 
and well differentiated (WD) esophageal squamous cell carcinoma 
with respect to adjacent normals (N). Vinculin polyclonal antibody was 
used as loading control (Lower Panel). B Upregulation of p66shc was 
also confirmed with antibody which reacts with all the three Shc iso-
forms. C Immunoblot showing the up-regulation of p66shc protein in 
esophageal adenocarcinoma. Vinculin antibody was used as loading 
control. D Densitiometric analysis of p66shc expression in esophageal 
squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) as com-
pared to adjacent normals (N). Columns, mean of fold increase in ex-
pression of four separate experiments, bars ± SE. * indicates stastically 
significant (p < 0.05) differences compared with adjacent normals as 
control using t test.Bashir et al. Cell Communication and Signaling 2010, 8:13
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It is generally accepted that rapid-growing cells have
activated metabolic reactions that lead to increased pro-
duction of ROS [20]. ROS [e.g., superoxide anion (O2
-),
hydrogen peroxide (H2O2), hydroxyl radical (OH), Peroxy
nitrite (ONOO-)] produced by inflammatory and epithe-
lial cells have been implicated in the development of
reflux esphagitis, Barrett's esophagus and adenocarci-
noma [21]. Based on this report, the p66shc molecule has
gained interest, since it is involved in the oxidative stress
signaling cascade leading to the production of H2O2 [6]
through p66Shc-Rac1pathway [9]. P66shc acts as a switch
t o  d i s s o c i a t e  S o s 1  f r o m  G r b 2 / S o s 1  p o o l  t o  E p s 8 / E 3 b 1
pool. This complex formation increases the generation of
oxidants through the activation of Rac1 protein [9]. Con-
versely, Expression of constitutively active Rac-1
increased phosphorylation, reduced ubiquitination and
increased stability of p66shc protein, thereby resulting in
further elevation of ROS [8]. This notion is further sup-
ported by the observations that raising intracellular ROS
level increases the expression of p66shc protein, for
example, by H2O2 treatment [3,22]. It is possible that this
signaling mechanism of p66Shc-Rac1-ROS is operative in
esophageal epithelial cells leading to carcinogenesis and
metastasis.
We also showed that the basal expression level of
p66shc in the controls of EAC was higher as against lower
levels found in the controls of ESCC. The activity of gas-
tric juices, bile acids and digestive enzymes are more pro-
nounced in lower gastrointestinal tract, which may be
responsible for higher physiological values of ROS in
EAC [23]. Our tissue study data corroborate our observa-
tions on the archival prostrate carcinoma (PCa) tissue
specimens that p66shc expression is lower in benign
glandular cells, whereas in adjacent adenocarcinomatous
cells, the expression of p66shc is higher [16]. Similarly,
the expression of p66shc was found to be increased in all
kinds of proliferating thyroid tissues, but not in the nor-
mal thyroid tissue of the same patient [24]. Collectively,
the data support our hypothesis that elevated p66shc pro-
tein in esophageal carcinomas plays a critical role in car-
cinogenesis.
We also observed similar expression of p66shc protein
levels in well, moderately and poorly differentiated
esophageal squamous cell carcinomas. Since all the sam-
ples taken for the study were in stage IIA of cancer devel-
opment, these results were quite evident. Hence, we are
unable to determine if the elevated p66Shc protein level
could serve as a diagnostic marker for esophageal cancer
progression. However, it can act as a useful prognostic
marker for stage IIA of cancers. The clinical application
of p66Shc protein in esophageal cancer progression
deserves further investigations
If p66shc participates in the carcinogenesis pathway,
then it must be exerting the effect through additional
d o w n s t r e a m  o r  u p s t r e a m  t a r g e t s .  P 6 6 s h c  i s  k n o w n  t o
promote trimeric complex formation involving Eps8,
E3b1 and Sos1, thus leading to an increase in rac1 activity
[10]. Hence we were interested in looking at the protein
expression level of those critical signaling associates of
p66shc which have been previously implicated in regulat-
ing cell proliferation i.e., Eps8 [25], and Rac1 [26] regulat-
ing the cytoskeletal organization. Results indicate that
Eps8 protein expression is higher in ESCC as well as EAC
(Figure 2A). We observed a higher level of Eps8 expres-
sion in well, moderately and poorly differentiated can-
cers. The results i.e., higher level of Eps8 expression in
tumors as compared to their adjacent normal was inde-
pendent of the grade of the cancers studied. Our results
are consistent with the previously observed studies car-
ried on different types of cancers [25,27,28]. We also
observed higher levels of Rac1 protein in cancerous sam-
ples relative to adjacent normal samples (Figure 2B). Our
densitometric analysis indicated 4-6 fold higher expres-
sion of Eps897 and 3-5 fold increase in expression of Rac1
in esophageal cancers compared to adjacent normal tis-
sue (Figure 2C).
Like p66shc we did find an increase in the basal levels
of Rac1 expression in EAC as compared to the ESCC.
Rac1 is associated with carcinogenesis and progression of
several human tumors [29-31]. Expression of constitu-
tively active Rac1 (Rac1V12) has been found to increase
phosphorylation, reduced ubiquitination, and increased
stability of p66shc protein. Furthermore, Rac1-stimulated
Table 1: Table representing distribution of patients and their classification into different cancer grades
Classification of 
Esophageal cancer
No. of patients Cancer grade Sex of patients No. of patients
Esophageal 65 well differentiated Male: 25; Female:10 35
Squamous cell moderately differentiated Male:12; Female:3 15
Carcinoma(ESCC) Poorly differentiated Male: 9; Female:6 15
Esophageal 
Adenocarcinoma (EAC)
35 Male:24; Female:11 35Bashir et al. Cell Communication and Signaling 2010, 8:13
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increase in expression of p66shc is dependent on intracel-
lular ROS suggesting that ROS generated by Rac1 activa-
tion may lie upstream of p66shc [9]. It is therefore
possible that increase in the expression of Rac1 leads to
the increase in the expression of p66shc through ROS in
esophageal cancers also.
It has been shown that p66shc forms stable complexes
with Grb2 [2]. However, during severe oxidative stress,
increased binding of p66shc to the activated EGFR and
Grb2 occurs. This binding dissociates the Sos1 adaptor
protein from the EGFR recruited signaling complex, lead-
ing to termination of Ras/MEK/ERK activation [12]. Thus
to support the antagonistic activity of p66shc towards
growth factor induced MAPK activation, we studied the
expression of Grb2 and Ras proteins in esophageal can-
cers. We observed (Figure 2D) equal expression of Grb2
in esophageal cancers with respect to adjacent normal.
We observed an increase in the Ras expression in ESCC
and EAC as compared to the normal (Figure 2D). It is
possible that the active Ras may even be higher in esoph-
ageal cancers as compared to the normal cells. Hence, we
do not rule out the possibility of p66shc participating in
the development of cancers through Grb2-Ras pathway in
addition to operating through Eps8-Rac1 pathway.
Figure 2 Expression of eps8, rac1, grb2 and ras proteins in esophageal cancers. Representative immunoblot showing the elevated levels of ex-
pression of A Eps8 from poorly differentiated (PD), Moderately differentiated (MD) and well differentiated (WD) esophageal squamous cell carcinoma 
and esophageal adenocarcinoma samples (lower panel). Vinculin polyclonal antibody was used as loading control. B Immunoblot analysis of Rac1, in 
the PD, MD, WD esophageal squamous and adenocarcinoma. C Immunoblot showing the expression of Grb2 and Ras proteins in PD, MD, WD esoph-
ageal squamous and adenocarcinoma. D Bar chart comparing the expression level of Eps8, Rac1, Grb2 and Ras proteins in esophageal cancers with 
respect to adjacent normals (N). Values are expressed as fold increase compared to adjacent normal. Columns, mean of fold increase in expression of 
four separate experiments, bars ± SE. * indicates stastically significant (p < 0.05) differences compared with adjacent normals as control using t test.Bashir et al. Cell Communication and Signaling 2010, 8:13
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Our data support for a novel functional role of p66shc
in esophageal cancers. We surmise a positive correlation
of p66shc, Eps8 and Rac1 in executing the signal leading
to excessive cell proliferation. Although p66shc can be
involved in ROS production [9], p66shc may be involved
in tumorigenesis through other pathways [32]. It is possi-
ble that this relationship between Rac1-mediated
increase in p66shc might lead to an increase in expression
of Eps8, which eventually might lead to the development
of cancer. Hence, determining other upstream effectors
and downstream regulators of p66shc may help to iden-
tify the mechanisms responsible for cancers and to design
strategies for the manipulation of their expression levels
in vivo.
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